Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat.com 3 Stocks You'll Wish You Bought Before 2026Written by Chris Markoch. Published 12/3/2025. 
Key Points - These three up-and-coming stocks have delivered triple-digit gains in 2025 and continue to show strong momentum.
- Key catalysts—including clinical milestones, revenue acceleration, and consumer demand—suggest more upside ahead.
- Analysts stay optimistic, with price targets suggesting possible double- or triple-digit gains from current levels.
Many investors profited from the artificial intelligence (AI) trade in 2025, but several up-and-coming stocks in other sectors also posted impressive gains this year. These three names remain small-cap — the largest has a market cap just above $4 billion — yet they've made strong moves, underscoring that time in the market often beats trying to time it. While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> If investors could see the future with absolute clarity, investing would be easy. The future is rarely clear, and a bullish outcome is not guaranteed. Still, the charts speak for themselves: investors who bought these stocks and held through rough stretches are reaping the rewards today, and the rallies may have room to continue. Biotech Breakthrough: A Small Cap With a Big 2026 FDA Catalyst Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company that recently reported positive clinical data for its first-in-class PI3K/mTOR inhibitor targeting HR+/HER2- metastatic breast cancer. Its pivotal Phase 3 VIKTORIA trial is underway, and some investors believe the company could receive U.S. Food & Drug Administration (FDA) approval in 2026. Investors have been front-running those expectations, pushing CELC stock up more than 660%, with nearly all of those gains occurring since the end of July. At $99.30 as of this writing, the stock sits within about 3% of its consensus price target. Meanwhile, Jefferies raised its price target on the stock to $134 from $108 on Dec. 2. The biggest risk is funding the commercialization phase. In its most recent earnings report, Celcuity showed a strengthened balance sheet with $455 million in cash, cash equivalents, and short-term investments, up about 72% year-over-year (YOY). Management believes those resources will be sufficient until commercialization begins. Fintech Disruptor Turning Revenue Growth Into Real Momentum At a time when traditional banks offer fewer affordable options, Dave Inc. (NASDAQ: DAVE) stands out. The Los Angeles-based fintech is best known for its Dave app. The app delivers affordable, transparent financial tools that help users — many living paycheck to paycheck — avoid overdraft fees, budget more effectively, and access short-term cash when needed. The company recently reported a 64% YOY increase in revenue and an 85% beat in adjusted earnings per share (EPS). DAVE stock is up roughly 120% in 2025, and analysts see further upside. As of this writing the stock trades at $208.24, and the consensus price target is $304.25 — more than 46% higher. Some investors may be wary of a forward price-to-earnings (P/E) ratio near 119. But analysts forecast earnings growth of roughly 117% over the next 12 months — growth that could justify a higher multiple as the company scales. Resale Retail Winner Riding a Massive Consumer Shift It's been another challenging year for consumer staples stocks, but ThredUp Inc. (NASDAQ: TDUP) has been a notable exception. TDUP is up more than 430% in 2025 despite a roughly 29% pullback during the three months ending Dec. 1. The company operates an online consignment marketplace — a model that resonates as many consumers tighten their budgets. The thrift and resale market was a $49 billion industry in 2024 and is projected to grow to $74 billion by 2029. TDUP is the smallest of the three names, and short interest above 17% indicates active trading. Still, the company's Q3 earnings showed strong year-over-year (YOY) revenue growth, record new-buyer acquisition, and a 37% YOY increase in orders. This could be a shorter-term, volatile trade. However, younger consumers — who form ThredUp's core market — are likely to remain budget-conscious for some time, which helps explain why analysts put TDUP's consensus price target at $12.50, roughly a 68% upside from its closing price on Dec. 1.
| 
